Cannabinoid company Cellular Goods has signed a manufacture and supply agreement with Chanelle McCoy Health, bringing forward the launch of its ingestible product range.
The UK-based provider of lab-made cannabinoid products, Cellular Goods, has signed a multi-year agreement with Ireland’s largest indigenous pharmaceutical company Chanelle McCoy Health for the manufacture and supply of its new range of clinically validated ingestible products. The agreement will bring the launch of the products forward by more than a year to Q4 of 2021.
Research-led developer of high-quality ultra-pure cannabinoid products that are fully compliant with the new novel food regime, Chanelle McCoy Health, will initially supply three CBD ingestible products under the agreement, which will go on sale under the Cellular Goods brand in the UK, followed by continental Europe in 2022.
Cellular Goods CEO, Alexis Abraham, said: “Chanelle McCoy Health was founded by pharmaceutical industry veterans who share our vision that consumers have a right to expect products which are safe, pure, clean and green; something lab-made cannabinoids alone can guarantee.
“Through this partnership we will be introducing consumers to novel food compliant CBD ingestibles that will complement our CBG skincare range. As a result we will launch this year with both CBD and CBG and two best in class product ranges; one of which is substantially earlier than we expected.”
New products to market
The products will be introduced to the market at the same time as the launch of Cellular Goods’ skincare range that will incorporate CBG in mid-December. The ingestible products will initially be sold exclusively through its the company’s new e-commerce website.
The products, which contain lab-made CBD which is bio-identical to plant-derived CBD, will include a tincture, spray and capsules that have already passed quality, safety and stability tests, comply with novel foods regulations in the UK and EU and are certified under Good Manufacturing Practice (GMP) standards.
Cellular Goods says that the deal will allow for immediate entry into the market segment, will expand the branded product range, provide access to a range of novel-food regulation-compliant products, reduce upfront R&D expenditure and provide the opportunity for future product development and research collaborations through access to compliant ultra-pure CBD and pharmaceutical expertise.
Chanelle McCoy Health co-founder and CEO, Lady McCoy, commented: “We are very excited to announce this commercial supply agreement of our ultra pure CBD. Consumers are searching for safe, certified, and reputable CBD products that are backed by clinical studies.
“This partnership will provide them choice and access to quality-assured CBD products containing 0% THC, an illegal narcotic, and free from toxins and pollutants. Cellular Goods and Chanelle McCoy Health are aligned in our pursuit to help break the stigma of CBD, educate and set the benchmark for the CBD industry.”
Cellular Goods says the deal marks a significant step in its go-to-market strategy, and a third line-up of products for athletic and everyday muscle recovery is due to be launched in Spring 2022.